191 related articles for article (PubMed ID: 38288195)
1. A Systematic Review of the Neuroprotective Effects of Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy and Diabetic Macular Edema: Unraveling the Molecular Mechanisms and Clinical Implications.
Yadav M; Grezenko H; Kanukollu VMR; Rehman A; Bokhari SFH; Reza T; Franco CD; Chilla SP; Fatima H; Choudhari J; Abdullah Yahya N; Amir M; Mohsin SN
Cureus; 2023 Dec; 15(12):e51351. PubMed ID: 38288195
[TBL] [Abstract][Full Text] [Related]
2. VEGF is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons.
Froger N; Matonti F; Roubeix C; Forster V; Ivkovic I; Brunel N; Baudouin C; Sahel JA; Picaud S
Sci Rep; 2020 Jul; 10(1):12409. PubMed ID: 32710087
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Liou GI; Caldwell RW
Curr Drug Targets; 2005 Jun; 6(4):511-24. PubMed ID: 16026270
[TBL] [Abstract][Full Text] [Related]
4. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far.
Whitmire W; Al-Gayyar MM; Abdelsaid M; Yousufzai BK; El-Remessy AB
Mol Vis; 2011 Jan; 17():300-8. PubMed ID: 21293735
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.
Nishijima K; Ng YS; Zhong L; Bradley J; Schubert W; Jo N; Akita J; Samuelsson SJ; Robinson GS; Adamis AP; Shima DT
Am J Pathol; 2007 Jul; 171(1):53-67. PubMed ID: 17591953
[TBL] [Abstract][Full Text] [Related]
6. Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Tsao YC; Chen TY; Wang LA; Lee CC; Lee WA; Hsu SM; Lai CC; Shao SC; Hung JH; Lai EC
BioDrugs; 2023 Nov; 37(6):843-854. PubMed ID: 37676536
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-A
Ved N; Hulse RP; Bestall SM; Donaldson LF; Bainbridge JW; Bates DO
Clin Sci (Lond); 2017 Jun; 131(12):1225-1243. PubMed ID: 28341661
[TBL] [Abstract][Full Text] [Related]
8. BI-Y, an Neuropilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of Retinopathies.
Thomas L; Low S; Hansen G; Bakker RA; Zippel N
J Pharmacol Exp Ther; 2023 Jun; 385(3):214-221. PubMed ID: 36997325
[TBL] [Abstract][Full Text] [Related]
9. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
[TBL] [Abstract][Full Text] [Related]
10. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.
Beazley-Long N; Hua J; Jehle T; Hulse RP; Dersch R; Lehrling C; Bevan H; Qiu Y; Lagrèze WA; Wynick D; Churchill AJ; Kehoe P; Harper SJ; Bates DO; Donaldson LF
Am J Pathol; 2013 Sep; 183(3):918-29. PubMed ID: 23838428
[TBL] [Abstract][Full Text] [Related]
11. VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases.
Le YZ
Vision Res; 2017 Oct; 139():108-114. PubMed ID: 28601428
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.
Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW
Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
[TBL] [Abstract][Full Text] [Related]
14. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
Stalmans I
Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858
[TBL] [Abstract][Full Text] [Related]
15. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy.
Tang L; Xu GT; Zhang JF
Neural Regen Res; 2023 May; 18(5):976-982. PubMed ID: 36254977
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
[TBL] [Abstract][Full Text] [Related]
18. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.
Zhao Y; Singh RP
Drugs Context; 2018; 7():212532. PubMed ID: 30181760
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic interventions for preventing macular edema after cataract surgery in patients with diabetes: A Bayesian network meta-analysis of randomized controlled trials.
Zhang R; Dong L; Yang Q; Liu Y; Li H; Zhou W; Wu H; Li Y; Li Y; Yu C; Wei W
EClinicalMedicine; 2022 Jul; 49():101463. PubMed ID: 35747191
[TBL] [Abstract][Full Text] [Related]
20. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.
Arrigo A; Aragona E; Bandello F
Ann Med; 2022 Dec; 54(1):1089-1111. PubMed ID: 35451900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
